BAY-3771249 (Not yet branded)

Description

BAY-3771249 is a targeted therapeutic agent directed against the KRAS G12D oncogenic mutation, one of the most prevalent and historically difficult-to-drug mutations in colorectal cancer. It is designed specifically for patients with advanced or metastatic colorectal cancer harboring the KRAS G12D variant, a mutation found in approximately 12-14% of all CRC cases. BAY-3771249 represents a direct KRAS inhibitor approach, built on the scientific advances that demonstrated mutant KRAS protein can be pharmacologically targeted through covalent or non-covalent binding strategies. A Phase 1 dose-escalation and dose-expansion study has assessed its safety profile and preliminary efficacy in this molecularly defined patient population.

Mechanism of Action

BAY-3771249 selectively targets the KRAS G12D mutant protein, a constitutively active GTPase that drives uncontrolled cell proliferation through continuous activation of the RAS-RAF-MEK-ERK and PI3K-AKT signaling cascades. By binding to the mutant KRAS G12D protein — exploiting the altered binding pocket created by the aspartate substitution at codon 12 — the drug locks KRAS in an inactive GDP-bound state, thereby suppressing downstream oncogenic signaling. This selective inhibition aims to spare wild-type KRAS activity, potentially improving the therapeutic index compared to broader RAS pathway inhibitors.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials